Empowering change through science
We are full life cycle investors supporting scientists and entrepreneurs at any stage where we identify opportunity, from academic programs in need of industry sponsorship all the way to mature publicly traded companies.
Rod dug in our company when many other investors disappeared. He did the work and realized BioCryst’s potential for treating rare diseases such as HAE long before others did.
RTW does deeper diligence than nearly any other investor I know. RTW’s research and guidance in the early days of Rainbow and noninvasive hemoglobin was a valuable resource. They helped us understand the opportunity and have been a trusted partner since.
The RTW Team spotted the argenx investment opportunity ahead of the curve and rapidly developed from an investor to a loyal partner. Their data based approach and desire to understand resonates very well with our company culture.
We view the team at RTW with highest regard. They believed in Alnylam's potential when the rest of the world was skeptical.
RTW uses scientific and clinical acumen to decipher critical investments. Rod and Piratip were excellent strategic partners who had the foresight to invest in Avexis.
Rod and the team at RTW dug deep into our science, saw our potential early and share our drive to bring science to patients. As a member of our board, Rod’s wisdom and guidance has been invaluable. RTW is more than an investor, they are a true partner.
RTW is a very insightful and strategic investment firm. They had the foresight to invest in PTC after our acquisition of Emflaza and have spent a significant amount of time and effort to understand the potential of our pipeline.
RTW is among the most thoughtful and diligent teams we have encountered. They saw the commercial potential of MACI early on, and have been a tremendous partner to Vericel during a period of rapid growth for the company.
RTW really took the time to understand our business, and they understood that the reasons that other people had said no were actually the very reasons to say yes. They backed us early and made good on their promise to be a true partner long after Establishment Labs' IPO. They are the entrepreneur's investor and a real value add.
RTW’s passion for science and rational approach toward therapeutics development have been essential to the RCKT story. Rod and team have an uncanny ability to identify opportunities that no one else has, well ahead of the curve, and the rigorous discipline to water them gently. We value them highly as top shareholders, as founders and integral members of the Board, and most importantly as friends.
The RTW team did deep commercial diligence into the potential for a prophylactic HAE medicine well before other investors. Combined with their deep understanding of science, RTW was a terrific long-term shareholder, as we advanced DX-2930 through the clinic and sought to bring this important therapy to patients.
The investments listed above include RTW funds’ investments in private companies that have had a liquidity event, or are investments of RTW Biotech Opportunities, Ltd. They do not include names of investments for which RTW is under non-disclosure obligations or in certain circumstances that are related to the protection of RTW’s competitive edge.
The discussion is included for informational purposes only and is intended to be illustrative but is not representative of transactions of a given type in which RTW may invest on behalf of the Funds. There can be no assurance that the Funds will achieve comparable results.
The above testimonials were given by CEOs or other senior executives of companies in which RTW has made an equity investment on behalf of managed funds. No compensation was provided to the individuals giving the testimonials. Joe Kiani and Guarav Shah are also investors in RTW managed funds. Stu Peltz is also a director of the board of Health Sciences Acquisitions Corporation 2, a SPAC sponsored by RTW Investments, LP, for which he has received stock grants in exchange for his service as a director. Since January 2022 John Maraganore has been an advisor to RTW Investments, LP, serving as Executive Partner.